Aastrom to Present at the Cowen 31st Annual Healthcare Conference
05 March 2011 - 2:28AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of
expanded autologous cellular therapies for the treatment of severe,
chronic cardiovascular diseases, today announced that company
president and CEO Tim Mayleben will speak at the Cowen 31st Annual
Healthcare Conference, which is being held March 7-9, 2011, at the
Boston Marriott Copley Place in Boston.
The Aastrom presentation will take place at 4 P.M. on Monday,
March 7, 2011. The presentation will be webcast live and will also
be accessible in archive until 11:59 P.M. (ET) on June 5, 2011,
beginning one hour after the presentation. The URL for live and
archived access to the presentation is
http://www.wsw.com/webcast/cowen3/astm/. Participants should
allow approximately five to ten minutes prior to the presentation
start time to visit the site and download any streaming media
software needed to listen to the webcast.
About Aastrom Biosciences
Aastrom Biosciences is developing expanded autologous cellular
therapies for use in the treatment of severe, chronic
cardiovascular diseases. The company's proprietary cell-processing
technology enables the manufacture of mixed-cell therapies expanded
from a patient's own bone marrow and delivered directly to damaged
tissues. Aastrom has advanced its cell therapies into late-stage
clinical development, including a planned Phase 3 clinical program
for the treatment of patients with critical limb ischemia and two
ongoing Phase 2 clinical trials in patients with dilated
cardiomyopathy. For more information, please visit Aastrom's
website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, the performance and contribution of
certain individuals and expected timing of collecting and analyzing
treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports
on Form 10-Q and other filings with the Securities and Exchange
Commission. These forward looking statements reflect management's
current views and Aastrom does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
CONTACT: Media and investor contact
Bill Berry
Berry & Company
212 253-8881
ir@aastrom.com
bberry@berrypr.com
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024